ErbB-2 receptor: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Meg Taylor (subpages) |
||
Line 1: | Line 1: | ||
{{subpages}} | |||
In [[biochemistry]], '''ErbB-2''' (Human Epidermal growth factor Receptor 2, HER2, HER-2) is a [[cell surface receptor]] that is a "[[protein-tyrosine kinase receptor]] that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor ([[epidermal growth factor receptor]]), the [[erbB-3 receptor]] and the erbB-4 receptor. Activation of the [[erbB-2 receptor]] occurs during heterodimer formation with a ligand-bound erbB receptor family members."<ref>{{MeSH}}</ref> | In [[biochemistry]], '''ErbB-2''' (Human Epidermal growth factor Receptor 2, HER2, HER-2) is a [[cell surface receptor]] that is a "[[protein-tyrosine kinase receptor]] that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor ([[epidermal growth factor receptor]]), the [[erbB-3 receptor]] and the erbB-4 receptor. Activation of the [[erbB-2 receptor]] occurs during heterodimer formation with a ligand-bound erbB receptor family members."<ref>{{MeSH}}</ref> | ||
==References== | ==References== | ||
<references/> | <references/> |
Revision as of 07:11, 30 September 2009
In biochemistry, ErbB-2 (Human Epidermal growth factor Receptor 2, HER2, HER-2) is a cell surface receptor that is a "protein-tyrosine kinase receptor that is found to be overexpressed in a significant number of adenocarcinomas. It has extensive homology to and can heterodimerize with the EGF receptor (epidermal growth factor receptor), the erbB-3 receptor and the erbB-4 receptor. Activation of the erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB receptor family members."[1]
References
- ↑ Anonymous (2024), ErbB-2 receptor (English). Medical Subject Headings. U.S. National Library of Medicine.